ACAD News 20.55 04/24/2014 20:51:17 Acadia Pharmaceuticals Inc

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acadia Pharmaceuticals Inc (ACAD) 20.55 $ACAD

Shares of ACAD Down 14.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 23, 11:20AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 4 weeks, Acadia Pharmaceuticals has returned 14.43% as of today's recent price of $20.31.

Acadia Pharmaceuticals Has Returned 21.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Apr 16, 9:37AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 3 weeks, Acadia Pharmaceuticals has returned 21.34% as of today's recent price of $18.67.

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

SmarTrend Watching for Potential Rebound in Shares of Acadia Pharmaceuticals After 6.41% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:11PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $16.95 to a high of $19.71. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $18.50 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 11.5% (ACAD)
Comtex SmarTrend(R) - Wed Apr 09, 9:21AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 weeks, Acadia Pharmaceuticals has returned 11.48% as of today's recent price of $21.01.

Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma

ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
Business Wire - Tue Apr 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City.

aTyr Pharma Appoints David M. Weiner, M.D., as Chief Medical Officer
PR Newswire - Fri Mar 28, 7:00AM CDT
aTyr Pharma ("aTyr" , a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders.

Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:

14.2% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Wed Mar 19, 9:26AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.21% as of today's recent price of $28.42.

Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:

ACADIA Pharmaceuticals prices public offering of 6.4m common shares
M2 - Wed Mar 05, 4:24AM CST
Biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) said on Tuesday that it has priced a public offering of 6,400,000 shares of its common stock.

ACADIA Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Mar 04, 6:28PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 960,000 shares of common stock. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.

ACADIA Pharmaceuticals plans to issue common stock in public offering
M2 - Tue Mar 04, 5:05AM CST
US-based biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) revealed on Monday that it intends to offer and sell USD150m of shares of its common stock in a public offering.

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Acadia Pharmaceuticals Shares Up 12.4% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Mon Mar 03, 10:02AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 12.44% as of today's recent price of $27.98.

ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 10:55AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Business Wire - Thu Feb 27, 3:02PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 55

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 0

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 175

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 11

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 72

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

Aterian Prepares for Upcoming Earnings Call This Quarter

Updated Category News Views 141

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Continue Reading
Updated Disclosure Insights for Balanced Commercial Property Trust

Updated Category News Views 70

Understanding the Recent Disclosure from Rathbones Group Plc Regarding Balanced Commercial Property Trust Limited This article offers a crucial overview of the recent disclosure made by Rathbones Group Plc about its interests in Balanced Commercial Property Trust Limited. Grasping these disclosures is essential for investors who want to effectively maneuver through the...

Continue Reading
TerraVolta Resources Secures Major Funding for Lithium Project

Updated Category News Views 219

TerraVolta Resources Lands Major Funding for Lithium Initiative Exciting developments are unfolding in the critical minerals sector as TerraVolta Resources, LLC, a key player in this field, has been chosen to negotiate a substantial $225 million funding award from the U.S. Department of Energy (DOE). This funding is set to support the establishment of a groundbreaking...

Continue Reading
Shining Moments of Natural Diamonds at the Golden Globes

Updated Category News Views 142

Shining Moments of Natural Diamonds at the Golden Globes This year's Golden Globes red carpet was captivating, showcasing natural diamonds that enchanted audiences and attendees alike. Rather than adhering to the conventional white diamond look, celebrities embraced a vibrant palette of colored diamonds. This trend was not just about sparkle but deeply reflected...

Continue Reading
iQIYI Plans Major Offering of Convertible Senior Notes

Updated Category News Views 122

iQIYI Plans a Significant Offering of Convertible Senior Notes iQIYI, Inc. (Nasdaq: IQ) is making headlines with its recent announcement regarding a substantial offering. The company plans to issue $300 million in convertible senior notes, reflecting its ongoing commitment to strengthen its financial position and enhance shareholder value. Details of the Convertible...

Continue Reading